Molecular profiling, biomarker detection, and in vivo imaging are reshaping how neurologists diagnose neurodegenerative ...

An outside advisory panel to the FDA is pushing for the production and sale of a few previously banned peptide treatments.

The FDA has approved Simtriyo (centanafadine), a first-in-class NDSRI and CNS stimulant, for adult and pediatric ADHD aged 6 years and older.

Older adults with traumatic brain injury may have an increased risk for neurologic conditions both before and after their injury.

Plasmapheresis is associated with improved outcomes among those who may not respond completely to steroids for treating MOGAD attacks.

Children with autism spectrum disorder may see improved gross motor skills with organized sports-based interventions.

The researchers found that years in which youth reported higher-than-usual, within-person problematic social media use were followed by elevations in parent-reported ADHD symptoms (years 4 to 5: β = 0 ...

The Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593 for the treatment of narcolepsy. Narcolepsy type 1 is a rare neurological condition caused ...

Midlife hypertension may be associated with lower semantic memory scores in adults aged 90 years and older, according to a recent study.

Despite questions about safety and regulation, there is still a strong market for compounded GLP-1 RA alternatives.

Kalshi and AppliedXL launch a pilot prediction market for late-stage clinical trial outcomes and FDA decisions using objective public data sources.

Up to 400 mg of caffeine each day is considered safe for most adults and may reduce the risk for certain cardiovascular conditions.